Bio-Rad Laboratories, Inc. (BIO) EV/FCF Ratio: 24.87x
Is Bio-Rad Laboratories, Inc.’s EV/FCF ratio high or low?
Bio-Rad Laboratories, Inc.'s EV/FCF ratio of 24.87x is 51% below its 5-year average of 51.13x, near the low end of its 5-year range (20.68x–198.52x).
The EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO) is 24.87x as of Tuesday, June 9, 2026. It is below its 12-month average by 0.58% (25.01x).
BIO EV/FCF Ratio Chart
BIO Average EV/FCF Ratio Chart
BIO Current vs Average EV/FCF Ratio Chart
BIO EV/FCF Ratio Metrics
EV/FCF RATIO
24.87x
EV/FCF RATIO AVG TTM
25.01x
EV/FCF RATIO AVG 3Y
43.94x
EV/FCF RATIO AVG 5Y
51.13x
EV/FCF RATIO AVG 10Y
112.67x
EV/FCF RATIO AVG 15Y
87.02x
EV/FCF RATIO AVG 20Y
75.24x
CURRENT VS TTM AVG
-0.58%
CURRENT VS 3Y AVG
-43.39%
CURRENT VS 5Y AVG
-51.36%
CURRENT VS 10Y AVG
-77.93%
CURRENT VS 15Y AVG
-71.42%
CURRENT VS 20Y AVG
-66.94%
BIO Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | — | 24.87x | 25.01x | 43.94x | 51.13x |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | 31.07x | 21.19x | 29.11x | 35.24x |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | 99.26x | 82.84x | 71.51x | 71.51x |
| Align Technology, Inc. (ALGN) | $12.76B | 17.17x | 17.74x | 29.63x | 39.00x |
| Hologic, Inc. (HOLX) | $16.97B | 17.53x | 16.89x | 18.61x | 15.13x |
| Moderna, Inc. (MRNA) | $18.94B | 27.77x | 20.23x | 39.97x | 29.53x |
| BioNTech SE (BNTX) | $21.87B | 9.68x | 18.15x | 9.84x | 13.27x |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 32.45x | 33.77x | 33.52x | 38.39x |
| Waters Corporation (WAT) | $24.19B | 134.83x | 42.98x | 42.91x | 41.35x |
| Veeva Systems Inc. (VEEV) | $27.37B | 50.23x | 29.28x | 32.90x | 38.29x |
Cash Flow Valuation Comparison
EV/FCF
24.9x
P/FCF
22.4x
FCF Yield
4.46%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Bio-Rad Laboratories, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The EV/FCF ratio for BIO stock is 24.87x.
- Is Bio-Rad Laboratories, Inc.'s EV/FCF ratio high or low?
- Bio-Rad Laboratories, Inc.'s EV/FCF ratio of 24.87x is 51% below its 5-year average of 51.13x, near the low end of its 5-year range (20.68x–198.52x).
- What is the TTM average EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average EV/FCF ratio for BIO stock is 25.01x.
- What is the 3Y average EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average EV/FCF ratio for BIO stock is 43.94x.
- What is the 5Y average EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average EV/FCF ratio for BIO stock is 51.13x.
- What is the 10Y average EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average EV/FCF ratio for BIO stock is 112.67x.
- What is the 15Y average EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average EV/FCF ratio for BIO stock is 87.02x.
- What is the 20Y average EV/FCF ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average EV/FCF ratio for BIO stock is 75.24x.
Bio-Rad Laboratories, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-03 | 25.44x |
| 2026-06-02 | 25.54x |
| 2026-06-01 | 25.49x |
| 2026-05-29 | 26.02x |
| 2026-05-28 | 26.45x |
| 2026-05-27 | 25.48x |
| 2026-05-26 | 24.85x |
| 2026-05-22 | 24.15x |
| 2026-05-21 | 24.08x |
| 2026-05-20 | 24.16x |
| 2026-05-19 | 23.65x |
| 2026-05-18 | 23.71x |
| 2026-05-15 | 21.12x |
| 2026-05-14 | 21.02x |
| 2026-05-13 | 20.82x |
| 2026-05-12 | 20.68x |
| 2026-05-11 | 20.84x |
| 2026-05-08 | 21.63x |
| 2026-05-07 | 21.86x |
| 2026-05-06 | 21.99x |
| 2026-05-05 | 21.84x |
| 2026-05-04 | 21.90x |
| 2026-05-01 | 21.80x |
| 2026-04-30 | 23.58x |
| 2026-04-29 | 22.51x |
| 2026-04-28 | 22.81x |
| 2026-04-27 | 23.38x |
| 2026-04-24 | 23.42x |
| 2026-04-23 | 22.96x |
| 2026-04-22 | 24.36x |
| 2026-04-21 | 24.71x |
| 2026-04-20 | 24.54x |
| 2026-04-17 | 24.23x |
| 2026-04-16 | 23.66x |
| 2026-04-15 | 24.01x |
| 2026-04-14 | 23.74x |
| 2026-04-13 | 23.45x |
| 2026-04-10 | 22.80x |
| 2026-04-09 | 22.68x |
| 2026-04-08 | 22.94x |
| 2026-04-07 | 22.71x |
| 2026-04-06 | 22.77x |
| 2026-04-02 | 22.86x |
| 2026-04-01 | 22.74x |
| 2026-03-31 | 22.77x |
| 2026-03-30 | 22.16x |
| 2026-03-27 | 21.81x |
| 2026-03-26 | 22.61x |
| 2026-03-25 | 22.40x |
| 2026-03-24 | 22.29x |
| 2026-03-23 | 21.78x |
| 2026-03-20 | 21.74x |
| 2026-03-19 | 21.78x |
| 2026-03-18 | 21.99x |
| 2026-03-17 | 22.10x |
| 2026-03-16 | 21.51x |
| 2026-03-13 | 21.62x |
| 2026-03-12 | 21.55x |
| 2026-03-11 | 22.13x |
| 2026-03-10 | 21.98x |
| 2026-03-09 | 22.24x |
| 2026-03-06 | 22.13x |
| 2026-03-05 | 22.79x |
| 2026-03-04 | 23.20x |
| 2026-03-03 | 22.87x |
| 2026-03-02 | 22.83x |
| 2026-02-27 | 22.75x |
| 2026-02-26 | 22.51x |
| 2026-02-25 | 22.11x |
| 2026-02-24 | 22.04x |
| 2026-02-23 | 22.01x |
| 2026-02-20 | 22.23x |
| 2026-02-19 | 22.27x |
| 2026-02-18 | 22.19x |
| 2026-02-17 | 21.77x |
| 2026-02-13 | 21.17x |
| 2026-02-12 | 23.75x |
| 2026-02-11 | 26.44x |
| 2026-02-10 | 26.94x |
| 2026-02-09 | 26.54x |
| 2026-02-06 | 27.07x |
| 2026-02-05 | 26.91x |
| 2026-02-04 | 27.42x |
| 2026-02-03 | 26.87x |
| 2026-02-02 | 26.74x |
| 2026-01-30 | 26.44x |
| 2026-01-29 | 26.54x |
| 2026-01-28 | 26.93x |
| 2026-01-27 | 26.76x |
| 2026-01-26 | 26.89x |
| 2026-01-23 | 26.67x |
| 2026-01-22 | 27.36x |
| 2026-01-21 | 27.87x |
| 2026-01-20 | 27.97x |
| 2026-01-16 | 28.03x |
| 2026-01-15 | 28.71x |
| 2026-01-14 | 28.41x |
| 2026-01-13 | 28.72x |
| 2026-01-12 | 28.79x |
| 2026-01-09 | 28.85x |
| 2026-01-08 | 28.47x |
| 2026-01-07 | 28.87x |
| 2026-01-06 | 28.99x |
| 2026-01-05 | 28.73x |
| 2026-01-02 | 27.37x |
| 2025-12-31 | 27.19x |
| 2025-12-30 | 27.31x |
| 2025-12-29 | 27.25x |
| 2025-12-26 | 27.26x |
| 2025-12-24 | 27.09x |
| 2025-12-23 | 27.03x |
| 2025-12-22 | 27.33x |
| 2025-12-19 | 27.07x |
| 2025-12-18 | 26.94x |
| 2025-12-17 | 27.05x |
| 2025-12-16 | 27.11x |
| 2025-12-15 | 27.58x |
| 2025-12-12 | 27.60x |
| 2025-12-11 | 28.06x |
| 2025-12-10 | 28.15x |
| 2025-12-09 | 27.59x |
| 2025-12-08 | 27.63x |
| 2025-12-05 | 28.36x |
| 2025-12-04 | 28.55x |
| 2025-12-03 | 28.57x |
| 2025-12-02 | 28.43x |
| 2025-12-01 | 28.67x |
| 2025-11-28 | 28.93x |
| 2025-11-26 | 29.11x |
| 2025-11-25 | 29.52x |
| 2025-11-24 | 28.74x |
| 2025-11-21 | 28.28x |
| 2025-11-20 | 27.24x |
| 2025-11-19 | 27.33x |
| 2025-11-18 | 27.57x |
| 2025-11-17 | 27.27x |
| 2025-11-14 | 28.00x |
| 2025-11-13 | 28.30x |
| 2025-11-12 | 29.13x |
| 2025-11-11 | 28.01x |
| 2025-11-10 | 27.54x |
| 2025-11-07 | 27.39x |
| 2025-11-06 | 27.47x |
| 2025-11-05 | 27.75x |
| 2025-11-04 | 27.82x |
| 2025-11-03 | 27.86x |
| 2025-10-31 | 28.51x |
| 2025-10-30 | 27.32x |
| 2025-10-29 | 28.50x |
| 2025-10-28 | 28.87x |
| 2025-10-27 | 29.32x |
| 2025-10-24 | 29.60x |
| 2025-10-23 | 29.52x |
| 2025-10-22 | 29.15x |
| 2025-10-21 | 28.94x |
| 2025-10-20 | 28.21x |
| 2025-10-17 | 27.27x |
| 2025-10-16 | 27.46x |
| 2025-10-15 | 26.95x |
| 2025-10-14 | 26.89x |
| 2025-10-13 | 26.78x |
| 2025-10-10 | 26.31x |
| 2025-10-09 | 26.54x |
| 2025-10-08 | 26.71x |
| 2025-10-07 | 26.22x |
| 2025-10-06 | 27.21x |
| 2025-10-03 | 26.92x |
| 2025-10-02 | 26.04x |
| 2025-10-01 | 26.33x |
| 2025-09-30 | 24.95x |
| 2025-09-29 | 24.15x |
| 2025-09-26 | 24.25x |
| 2025-09-25 | 24.17x |
| 2025-09-24 | 24.66x |
| 2025-09-23 | 25.08x |
| 2025-09-22 | 25.19x |
| 2025-09-19 | 25.24x |
| 2025-09-18 | 25.43x |
| 2025-09-17 | 24.95x |
| 2025-09-16 | 25.10x |
| 2025-09-15 | 24.94x |
| 2025-09-12 | 24.95x |
| 2025-09-11 | 25.38x |
| 2025-09-10 | 24.68x |
| 2025-09-09 | 25.39x |
| 2025-09-08 | 25.74x |
| 2025-09-05 | 26.13x |
| 2025-09-04 | 25.66x |
| 2025-09-03 | 25.55x |
| 2025-09-02 | 25.76x |
| 2025-08-29 | 26.32x |
| 2025-08-28 | 25.99x |
| 2025-08-27 | 25.93x |
| 2025-08-26 | 26.22x |
| 2025-08-25 | 26.28x |
| 2025-08-22 | 26.79x |
| 2025-08-21 | 25.32x |
| 2025-08-20 | 25.56x |
| 2025-08-19 | 25.58x |
| 2025-08-18 | 25.29x |
| 2025-08-15 | 25.37x |
| 2025-08-14 | 25.49x |
| 2025-08-13 | 25.48x |
| 2025-08-12 | 24.51x |
| 2025-08-11 | 23.71x |
| 2025-08-08 | 23.69x |
| 2025-08-07 | 23.77x |
| 2025-08-06 | 23.69x |
| 2025-08-05 | 24.31x |
| 2025-08-04 | 24.67x |
| 2025-08-01 | 25.28x |
| 2025-07-31 | 21.94x |
| 2025-07-30 | 23.61x |
| 2025-07-29 | 23.82x |
| 2025-07-28 | 23.87x |
| 2025-07-25 | 24.79x |
| 2025-07-24 | 24.61x |
| 2025-07-23 | 24.19x |
| 2025-07-22 | 23.22x |
| 2025-07-21 | 23.11x |
| 2025-07-18 | 23.30x |
| 2025-07-17 | 23.57x |
| 2025-07-16 | 23.37x |
| 2025-07-15 | 23.38x |
| 2025-07-14 | 23.67x |
| 2025-07-11 | 24.19x |
| 2025-07-10 | 24.43x |
| 2025-07-09 | 23.86x |
| 2025-07-08 | 23.66x |
| 2025-07-07 | 23.35x |
| 2025-07-03 | 23.73x |
| 2025-07-02 | 23.65x |
| 2025-07-01 | 23.43x |
| 2025-06-30 | 22.87x |
| 2025-06-27 | 23.09x |
| 2025-06-26 | 23.05x |
| 2025-06-25 | 22.84x |
| 2025-06-24 | 22.58x |
| 2025-06-23 | 22.38x |
| 2025-06-20 | 22.48x |
| 2025-06-18 | 22.08x |
| 2025-06-17 | 21.95x |
| 2025-06-16 | 22.06x |
| 2025-06-13 | 21.66x |
| 2025-06-12 | 22.12x |
| 2025-06-11 | 21.93x |
| 2025-06-10 | 21.96x |
| 2025-06-09 | 21.54x |
| 2025-06-06 | 21.02x |
| 2025-06-05 | 21.02x |
| 2025-06-04 | 21.25x |
| 2025-06-03 | 21.12x |
| 2025-06-02 | 20.78x |
| 2025-05-30 | 21.66x |
| 2025-05-29 | 21.71x |
| 2025-05-28 | 21.84x |
| 2025-05-27 | 21.95x |
| 2025-05-23 | 21.39x |
| 2025-05-22 | 21.67x |
| 2025-05-21 | 21.75x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz